Qianjiang Yongan Pharmaceutical Co Ltd Net Assets
Qianjiang Yongan Pharmaceutical Co Ltd net assets. Based on the latest financial reports, Qianjiang Yongan Pharmaceutical Co Ltd (002365) has net assets worth CN¥2.02 Billion CNY (≈ $294.89 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.26 Billion ≈ $331.06 Million USD) and total liabilities (CN¥247.20 Million ≈ $36.17 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Qianjiang Yongan Pharmaceutical Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.02 Billion |
| % of Total Assets | 89.07% |
| Annual Growth Rate | 17.92% |
| 5-Year Change | 12.58% |
| 10-Year Change | 82.41% |
| Growth Volatility | 49.8 |
Net Assets of Qianjiang Yongan Pharmaceutical Co Ltd (2006–2024)
Net assets of Qianjiang Yongan Pharmaceutical Co Ltd from 2006 to 2024. This chart illustrates how Qianjiang Yongan Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Qianjiang Yongan Pharmaceutical Co Ltd (002365) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Qianjiang Yongan Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual net assets of Qianjiang Yongan Pharmaceutical Co Ltd from 2006 to 2024. For live market cap and overall valuation, see Qianjiang Yongan Pharmaceutical Co Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.04 Billion ≈ $298.82 Million |
-0.30% |
| 2023-12-31 | CN¥2.05 Billion ≈ $299.73 Million |
-2.60% |
| 2022-12-31 | CN¥2.10 Billion ≈ $307.74 Million |
+7.46% |
| 2021-12-31 | CN¥1.96 Billion ≈ $286.37 Million |
+7.89% |
| 2020-12-31 | CN¥1.81 Billion ≈ $265.42 Million |
+9.48% |
| 2019-12-31 | CN¥1.66 Billion ≈ $242.43 Million |
+3.16% |
| 2018-12-31 | CN¥1.61 Billion ≈ $235.00 Million |
+19.43% |
| 2017-12-31 | CN¥1.34 Billion ≈ $196.77 Million |
+14.24% |
| 2016-12-31 | CN¥1.18 Billion ≈ $172.25 Million |
+5.15% |
| 2015-12-31 | CN¥1.12 Billion ≈ $163.82 Million |
+1.05% |
| 2014-12-31 | CN¥1.11 Billion ≈ $162.12 Million |
+2.60% |
| 2013-12-31 | CN¥1.08 Billion ≈ $158.02 Million |
-1.31% |
| 2012-12-31 | CN¥1.09 Billion ≈ $160.11 Million |
+3.59% |
| 2011-12-31 | CN¥1.06 Billion ≈ $154.57 Million |
+4.11% |
| 2010-12-31 | CN¥1.01 Billion ≈ $148.46 Million |
+212.97% |
| 2009-12-31 | CN¥324.17 Million ≈ $47.44 Million |
+25.11% |
| 2008-12-31 | CN¥259.12 Million ≈ $37.92 Million |
+35.29% |
| 2007-12-31 | CN¥191.53 Million ≈ $28.03 Million |
+82.44% |
| 2006-12-31 | CN¥104.99 Million ≈ $15.36 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Qianjiang Yongan Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2383.2% over the analyzed period, indicating profitable operations and earnings retention.
Qianjiang Yongan Pharmaceutical Co Ltd Net Assets Breakdown (December 2024)
Qianjiang Yongan Pharmaceutical Co Ltd net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥837.23 Million | 41.99% |
| Common Stock | CN¥294.68 Million | 14.78% |
| Other Comprehensive Income | CN¥173.29 Million | 8.69% |
| Other Components | CN¥688.58 Million | 34.54% |
| Total Equity | CN¥1.99 Billion | 100.00% |
Qianjiang Yongan Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Qianjiang Yongan Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Baosight Software Co Ltd B
SHG:900926
|
$517.55 Million |
|
W&T Offshore Inc
NYSE:WTI
|
$517.73 Million |
|
Potbelly Co
NASDAQ:PBPB
|
$517.96 Million |
|
SD Biosensor Inc
KO:137310
|
$518.00 Million |
|
Zhongjin Irradiation Incorporated Company
SHE:300962
|
$517.28 Million |
|
Grenevia S.A.
WAR:GEA
|
$517.18 Million |
|
Shanghai Golden Bridge
SHG:603918
|
$517.17 Million |
|
Savita Oil Technologies Limited
NSE:SOTL
|
$517.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Qianjiang Yongan Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,983,913,143 to 1,993,780,889, a change of 9,867,746 (0.5%).
- Net income of 61,766,022 contributed positively to equity growth.
- Dividend payments of 29,816,071 reduced retained earnings.
- Share repurchases of 24,183,171 reduced equity.
- Other comprehensive income increased equity by 9,529,865.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥61.77 Million | +3.1% |
| Dividends Paid | CN¥29.82 Million | -1.5% |
| Share Repurchases | CN¥24.18 Million | -1.21% |
| Other Comprehensive Income | CN¥9.53 Million | +0.48% |
| Other Changes | CN¥-7.43 Million | -0.37% |
| Total Change | CN¥- | 0.50% |
Book Value vs Market Value Analysis
This analysis compares Qianjiang Yongan Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.75x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 18.86x to 1.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | CN¥0.64 | CN¥12.00 | x |
| 2007-12-31 | CN¥1.02 | CN¥12.00 | x |
| 2008-12-31 | CN¥1.23 | CN¥12.00 | x |
| 2009-12-31 | CN¥1.54 | CN¥12.00 | x |
| 2010-12-31 | CN¥3.81 | CN¥12.00 | x |
| 2011-12-31 | CN¥3.73 | CN¥12.00 | x |
| 2012-12-31 | CN¥3.87 | CN¥12.00 | x |
| 2013-12-31 | CN¥3.75 | CN¥12.00 | x |
| 2014-12-31 | CN¥3.95 | CN¥12.00 | x |
| 2015-12-31 | CN¥3.80 | CN¥12.00 | x |
| 2016-12-31 | CN¥4.14 | CN¥12.00 | x |
| 2017-12-31 | CN¥4.60 | CN¥12.00 | x |
| 2018-12-31 | CN¥5.45 | CN¥12.00 | x |
| 2019-12-31 | CN¥5.59 | CN¥12.00 | x |
| 2020-12-31 | CN¥6.09 | CN¥12.00 | x |
| 2021-12-31 | CN¥6.33 | CN¥12.00 | x |
| 2022-12-31 | CN¥6.85 | CN¥12.00 | x |
| 2023-12-31 | CN¥6.73 | CN¥12.00 | x |
| 2024-12-31 | CN¥6.85 | CN¥12.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Qianjiang Yongan Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.36%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.16x
- Recent ROE (3.10%) is below the historical average (11.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 35.68% | 23.91% | 1.04x | 1.44x | CN¥26.96 Million |
| 2007 | 36.00% | 21.89% | 1.24x | 1.33x | CN¥49.80 Million |
| 2008 | 39.59% | 22.92% | 1.18x | 1.46x | CN¥76.67 Million |
| 2009 | 20.07% | 20.96% | 0.79x | 1.22x | CN¥32.64 Million |
| 2010 | 4.54% | 14.42% | 0.29x | 1.08x | CN¥-55.35 Million |
| 2011 | 6.61% | 16.73% | 0.36x | 1.10x | CN¥-35.86 Million |
| 2012 | 6.89% | 16.01% | 0.39x | 1.11x | CN¥-34.06 Million |
| 2013 | 2.13% | 4.40% | 0.43x | 1.11x | CN¥-84.98 Million |
| 2014 | 2.86% | 4.82% | 0.55x | 1.07x | CN¥-79.07 Million |
| 2015 | 1.58% | 3.17% | 0.46x | 1.08x | CN¥-93.93 Million |
| 2016 | 5.31% | 11.34% | 0.43x | 1.09x | CN¥-55.04 Million |
| 2017 | 9.93% | 14.27% | 0.59x | 1.18x | CN¥-961.31K |
| 2018 | 11.30% | 17.76% | 0.52x | 1.22x | CN¥20.59 Million |
| 2019 | 5.58% | 6.56% | 0.72x | 1.18x | CN¥-71.36 Million |
| 2020 | 6.01% | 9.00% | 0.54x | 1.23x | CN¥-70.01 Million |
| 2021 | 5.97% | 7.12% | 0.68x | 1.23x | CN¥-75.18 Million |
| 2022 | 6.96% | 9.60% | 0.60x | 1.20x | CN¥-61.39 Million |
| 2023 | -0.62% | -1.27% | 0.41x | 1.18x | CN¥-210.70 Million |
| 2024 | 3.10% | 7.36% | 0.36x | 1.16x | CN¥-137.61 Million |
Industry Comparison
This section compares Qianjiang Yongan Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,405,673
- Average return on equity (ROE) among peers: 7.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Qianjiang Yongan Pharmaceutical Co Ltd (002365) | CN¥2.02 Billion | 35.68% | 0.12x | $517.46 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $488.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $560.87 Million | 4.60% | 0.22x | $360.39 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.02 Billion | 12.46% | 0.13x | $4.73 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.04 Billion | 4.29% | 0.46x | $2.58 Billion |
| Wedge Industrial Co Ltd (000534) | $0.00 | 0.00% | 0.00x | $1.20 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $18.14 Billion | 17.33% | 0.53x | $14.52 Billion |
| Hainan Haiyao Co Ltd (000566) | $491.82 Million | 6.71% | 1.19x | $755.58 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $280.91 Million | 1.46% | 1.58x | $272.98 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.57 Billion | 7.36% | 1.59x | $920.83 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $7.25 Billion | 17.08% | 0.09x | $3.02 Billion |
About Qianjiang Yongan Pharmaceutical Co Ltd
Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmace… Read more